Azilsartan: Current Evidence and Perspectives in Management of Hypertension

Table 1

Pivotal trials of ARB’s and their key findings.

ARB	Major trials	Number of patients	Year	Major findings
Losartan	LIFE [8]	9193	2002	Losartan prevents more cardiovascular morbidity and death than atenolol for similar reduction in blood pressure and is better tolerated. Losartan seems to confer benefits beyond reduction in blood pressure
Telmesartan	ONTARGET [9]	25,620	2008	Telmisartan was equivalent to ramipril in patients with vascular disease or high-risk diabetes and was associated with less angioedema. The combination of the two drugs was associated with more adverse events without an increase in benefit
Olmesartan	ROADMAP [10]	1147	2015	Additive treatment with an angiotensin receptor blocker, olmesartan, did not improve clinical outcome in hypertensive patients with chronic heart failure (CHF) treated with angiotensin-converting enzyme (ACE) inhibitors, β-blockers, or both
Valsartan	VALUE [11]	15,425	2004	The hypothesis with equivalent amount of blood pressure control, valsartan would reduce cardiac morbidity and mortality more than amlodipine in hypertensive patients with high cardiovascular risk could not be proved; Unequal reductions in blood pressure might account for differences between the groups in cause-specific outcomes. The findings emphasise the importance of prompt blood-pressure control in hypertensive patients with high cardiovascular risk